Potential time benefit in the assessment of recurrent rat rhabdomyosarcoma using positron emission tomography (PET) with (18)fluorodeoxyglucose depends on therapy-specific growth delay

Strahlenther Onkol. 2006 Oct;182(10):610-5. doi: 10.1007/s00066-006-1553-5.

Abstract

Purpose: To correlate the potential time benefit of (18)F-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) in terms of early detection of recurrences of subcutaneously growing R1H tumors with therapy-specific parameters of recurrent tumor.

Material and methods: Twelve, eleven, and seven recurrences were followed after fractionated radiotherapy, surgery, and chemotherapy for 6 months, respectively, and (18)FDG-PET was performed weekly using a conventional full-ring whole-body PET scanner. By comparing PET results and actual tumor volume, the time benefit of (18)FDG-PET in detection of recurrent tumors of 0.1, 0.2, and 0.5 cm(3) was determined for the different treatment strategies.

Results: A significant time benefit of (18)FDG-PET of 26.9 days and 67 days was solely determined for recurrences after radiotherapy of 0.2 cm(3) and 0.5 cm(3), respectively. The potential time benefit showed a strong correlation with growth delay, which was increased after radiotherapy due to a pronounced tumor-bed effect.

Conclusion: The potential time benefit of (18)FDG-PET is strongly determined by the growth kinetics of the recurrence. A tumor-bed effect, which is a phenomenon solely seen after radiotherapy, favors early detection by (18)FDG-PET. The experimental data, clinical experience and theoretical consideration all indicate a noticeable benefit of (18)FDG-PET especially after radiotherapeutic treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Feasibility Studies
  • Fluorodeoxyglucose F18*
  • Neoplasm Recurrence, Local / diagnostic imaging*
  • Neoplasm Recurrence, Local / radiotherapy*
  • Positron-Emission Tomography / methods*
  • Radiopharmaceuticals
  • Rats
  • Reproducibility of Results
  • Rhabdomyosarcoma / diagnostic imaging*
  • Rhabdomyosarcoma / radiotherapy*
  • Sensitivity and Specificity
  • Time Factors

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18